β-Secretase Inhibitor IV可与BACE-1活性位点结合并有效阻断其蛋白水解活性(IC₅₀=15nM)。
Cas No.:797035-11-1
Sample solution is provided at 25 µL, 10mM.
β-Secretase Inhibitor IV binds to the active site of BACE-1 and effectively blocks its proteolytic activity (IC₅₀=15nM)[1-2]. β-Secretase Inhibitor IV reduces the production of amyloid-β peptide by inhibiting the β-secretase cleavage site of amyloid precursor protein. β-Secretase Inhibitor IV can be used in research related to neurodegenerative diseases such as Alzheimer's disease[3-4].
In vitro, β-Secretase Inhibitor IV (0.36μM) was incubated with mouse Neuro2a (N2a) cells for 24 hours, which inhibited the secretion of amyloid-β peptide Aβ40[5]. β-Secretase Inhibitor IV (29nM) was incubated with HEK293FT cells for 6 hours. β-Secretase Inhibitor IV significantly inhibited intracellular BACE-1 activity[6].
In vivo, a single intraperitoneal injection of β-Secretase Inhibitor IV (8mg/kg) was administered to Tg2576 transgenic mice expressing amyloid precursor protein (APP). After 4 hours, β-Secretase Inhibitor IV significantly reduced plasma Aβ40 levels[7].
References:
[1] Z Pietrak BL, Crouthamel MC, Tugusheva K, et al. Biochemical and cell-based assays for characterization of BACE-1 inhibitors. Anal Biochem. 2005 Jul 1;342(1):144-51.
[2] Cheng XR, Zhou JW, Zhou Y, et al. The green tea polyphenol (2)-epigallocatechin-3-gallate (EGCG) is not a β-secretase inhibitor. Bioorg Med Chem Lett. 2012 Feb 1;22(3):1408-14.
[3] Zhu YP, Xiao K, Yu HP, et al. Discovery of potent beta-secretase (bace-1) inhibitors by the synthesis of isophthalamide-containing hybrids. Acta Pharmacol Sin. 2009 Feb;30(2):259-69.
[4] Nordeman P, Estrada S, Odell LR, et al. (11)C-Labeling of a potent hydroxyethylamine BACE-1 inhibitor and evaluation in vitro and in vivo. Nucl Med Biol. 2014 Jul;41(6):536-43.
[5] Garino C, Tomita T, Pietrancosta N, et al. Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays. J Med Chem. 2006 Jul 13;49(14):4275-85.
[6] Choi SJ, Cho JH, Im I, et al. Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors. Eur J Med Chem. 2010 Jun;45(6):2578-90.
[7] Ghosh AK, Kumaragurubaran N, Hong L, et al. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407.
β-Secretase Inhibitor IV可与BACE-1活性位点结合并有效阻断其蛋白水解活性(IC₅₀=15nM)[1-2]。β-Secretase Inhibitor IV通过抑制淀粉样前体蛋白的β-分泌酶裂解位点来减少淀粉样β肽的产生。β-Secretase Inhibitor IV可用于阿尔茨海默病等神经退行性疾病的相关研究[3-4]。
在体外,β-Secretase Inhibitor IV(0.36μM)孵育小鼠Neuro2a(N2a)细胞24小时,可抑制细胞分泌的淀粉样β肽Aβ40[5]。β-Secretase Inhibitor IV(29nM)孵育HEK293FT细胞6小时。β-Secretase Inhibitor IV显著抑制胞内BACE-1活性[6]。
在体内,β-Secretase Inhibitor IV(8mg/kg)单次腹腔注射于表达淀粉样前体蛋白(APP)的Tg2576转基因小鼠模型。在4小时后,β-Secretase Inhibitor IV可显著降低血浆中的Aβ40水平[7]。
| Cell experiment [1]: | |
Cell lines | Mouse Neuro2a (N2a) cells (mouse neuroblastoma cell line) |
Preparation Method | Cells were plated in 24-well plates and cultured to confluency. β-Secretase Inhibitor IV was diluted from a DMSO stock solution into the culture medium to yield a final concentration of 0.1% DMSO. |
Reaction Conditions | 0.36μM; 24h. |
Applications | β-Secretase Inhibitor IV inhibited the secretion of amyloid-β peptide Aβ40 from the cells. |
| Animal experiment [2]: | |
Animal models | Tg2576 transgenic mice (an Alzheimer's disease model) |
Preparation Method | Mice received a single intraperitoneal (i.p.) administration of β-Secretase Inhibitor IV (8mg/kg). |
Dosage form | 8mg/kg; i.p.; single injection. |
Applications | Administration of β-Secretase Inhibitor IV resulted in a 30% reduction of plasma Aβ40 levels at 4 hours post-injection. The observed inhibition of Aβ40 production was statistically significant. |
References: | |
| Cas No. | 797035-11-1 | SDF | |
| 化学名 | N1-[(1S,2R)-3-(cyclopropylamino)-2-hydroxy-1-(phenylmethyl)propyl]-5-[methyl(methylsulfonyl)amino]-N3-[(1R)-1-phenylethyl]-1,3-benzenedicarboxamide | ||
| Canonical SMILES | CN(S(C)(=O)=O)C1=CC(C(N[C@H](C)C2=CC=CC=C2)=O)=CC(C(N[C@@H](CC3=CC=CC=C3)[C@H](O)CNC4CC4)=O)=C1 | ||
| 分子式 | C31H38N4O5S | 分子量 | 578.7 |
| 溶解度 | 10mg/mL in ethanol, 20mg/mL in DMSO or in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.728 mL | 8.6401 mL | 17.2801 mL |
| 5 mM | 345.6 μL | 1.728 mL | 3.456 mL |
| 10 mM | 172.8 μL | 864 μL | 1.728 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















